2021 started off well for Dana-Farber Cancer Institute, with the launch of its new venture fund, Binney Street Capital, LLC, designed to invest in cutting edge technology to treat incurable cancers.

The cancer-fighting giant tapped Roche and Verily veteran Luba Greenwood to lead the Fund as its Managing Partner, which will be guided by an advisory group comprised of leading industry experts and investors focused on furthering Dana-Farber’s mission.  

More than 51 startups, including over 11 in just the past 3 years, have reportedly been created with research, IP and/or leadership sourced from Dana Farber.  The Institute has responded by launching the fund to invest in and support such companies as a means to the end of developing new and advanced therapies for patients.

Investments will reportedly be made in companies that were created with Dana-Farber IP or co-founded by a Dana-Farber investigator, and that focus primarily on therapeutics but in some cases novel diagnostics, digital health, and services also. 

Greenwood has indicated that Binney Street plans to invest in 8 to 10 companies over the next three years, with $250K – $2M per investment.  “The science has to be differentiated, it has to be truly break-through…” Greenwood said. “So basically the best of the best in oncology and immunology.”

Here are some posts relating to the launch of this fund for your reference: EndPoints News  Fierce Biotech  Dana-Farber Cancer Institute

Disclaimer: The information contained in this posting does not, and is not intended to, constitute legal advice or express any opinion to be relied up legally, for investment purposes or otherwise. If you would like to obtain legal advice relating to the subject matter addressed in this posting, please consult with us or your attorney. The information in this post is also based upon publicly available information, presents opinions, and does not represent in any way whatsoever the opinions or official positions of the entities or individuals referenced herein.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Dan Shores Dan Shores

Dan Shores is a partner at  Rothwell, Figg and founder of its Boston office. He serves companies operating in dynamic biotech and other markets building patent portfolios, litigating complex patent disputes, negotiating strategic collaborations, and conducting due diligence and landscape investigations. Dan has…

Dan Shores is a partner at  Rothwell, Figg and founder of its Boston office. He serves companies operating in dynamic biotech and other markets building patent portfolios, litigating complex patent disputes, negotiating strategic collaborations, and conducting due diligence and landscape investigations. Dan has served companies utilizing the following technologies (without limitation): mRNA; lipid nanoparticles; CAR-T; oligonucleotides; genetically engineered swine organs for xenotransplantation; artificial intelligence for drug discovery; small molecules; biologics, materials science, and numerous other technologies throughout his 20-year career. Dan has a B.S. in engineering with a specialization in materials science from the University of New Hampshire and a J.D. from the Georgetown University Law Center. He is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts.